Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRTXNYSEAMERICAN:CCELNASDAQ:KDLYNASDAQ:OPGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXBioRestorative Therapies$1.61-3.6%$1.76$1.03▼$2.55$12.08M77.73543,037 shs31,661 shsCCELCryo-Cell International$5.01$5.71$4.75▼$9.49$40.38M0.5312,428 shs16,478 shsKDLYKindly MD$12.95-6.6%$2.86$0.65▼$31.45$77.99MN/A1.89 million shs4.53 million shsOPGNOpGen$4.90+4.3%$3.93$0.53▼$5.30$49.33M-1.7110,637 shs4,869 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXBioRestorative Therapies0.00%-10.56%-8.00%-29.69%+17.52%CCELCryo-Cell International0.00%-0.79%-13.92%-4.75%-4.75%KDLYKindly MD0.00%+229.52%+640.00%+348.10%+1,294,999,900.00%OPGNOpGen0.00%-0.20%+17.51%+255.07%+11.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRTXBioRestorative Therapies3.4534 of 5 stars3.55.00.00.01.03.31.3CCELCryo-Cell International3.0921 of 5 stars3.55.01.70.00.01.70.0KDLYKindly MD1.0858 of 5 stars0.05.00.00.02.51.70.0OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXBioRestorative Therapies 3.00Buy$18.001,018.01% UpsideCCELCryo-Cell International 3.00Buy$8.5069.66% UpsideKDLYKindly MD 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BRTX, KDLY, CCEL, and OPGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2025CCELCryo-Cell InternationalMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.50(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXBioRestorative Therapies$401K30.13N/AN/A$2.45 per share0.66CCELCryo-Cell International$31.34M1.29$0.41 per share12.09($1.33) per share-3.77KDLYKindly MD$2.47M31.57N/AN/AN/A∞OPGNOpGen$2.67M18.46N/AN/A($11.55) per share-0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXBioRestorative Therapies-$14.41M-$1.16N/AN/AN/A-2,697.08%-98.49%-75.23%N/ACCELCryo-Cell International-$9.52M-$1.06N/A∞N/A-28.03%-42.06%7.06%N/AKDLYKindly MDN/A-$0.77N/A∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)Latest BRTX, KDLY, CCEL, and OPGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BRTXBioRestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million5/8/2025Q1 2025KDLYKindly MDN/A-$0.17N/A-$0.17N/AN/A3/28/2025Q4 2024KDLYKindly MDN/A-$0.17N/A-$0.17N/A$0.60 million3/27/2025Q4 2024BRTXBioRestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXBioRestorative TherapiesN/AN/AN/AN/AN/ACCELCryo-Cell International$1.0019.96%N/AN/A N/AKDLYKindly MDN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ALatest BRTX, KDLY, CCEL, and OPGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/8/2025CCELCryo-Cell Internationalquarterly$0.1511.79%5/21/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXBioRestorative TherapiesN/A2.952.95CCELCryo-Cell InternationalN/A0.610.57KDLYKindly MDN/A5.435.42OPGNOpGenN/A5.455.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXBioRestorative Therapies69.38%CCELCryo-Cell International10.44%KDLYKindly MDN/AOPGNOpGen2.68%Insider OwnershipCompanyInsider OwnershipBRTXBioRestorative Therapies25.50%CCELCryo-Cell International36.86%KDLYKindly MD50.50%OPGNOpGen43.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXBioRestorative Therapies77.51 million5.16 millionNot OptionableCCELCryo-Cell International908.06 million5.09 millionNot OptionableKDLYKindly MDN/A6.02 million2.96 millionN/AOPGNOpGen10010.07 million4.70 millionNot OptionableBRTX, KDLY, CCEL, and OPGN HeadlinesRecent News About These CompaniesOpGen Delays 10-Q Filing Amid Operational ChallengesMay 16 at 6:55 PM | tipranks.comOpGen (NASDAQ:OPGN) Now Covered by StockNews.comMay 13, 2025 | americanbankingnews.comOpGen Inc ziet aanzienlijke aankoop van aandelen door AEI Capital LtdDecember 11, 2024 | nl.investing.comOpGen Inc aandeelhouder AEI Capital Ltd verhoogt belang met aankoop van €1,9 biljoenDecember 10, 2024 | nl.investing.comOpGen Appoints New COO and Company SecretaryDecember 6, 2024 | tipranks.comOpGen (OTC:OPGN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comOPGN Stock Earnings: OpGen Reported Results for Q2 2024August 21, 2024 | investorplace.comOPGN Stock Earnings: OpGen Reported Results for Q1 2024July 8, 2024 | investorplace.comOPGN Stock Earnings: OpGen Meets Revenue for Q4 2023June 5, 2024 | investorplace.comOpgen Inc (NASDAQ:OPGN) stock Posted Gross Margin of 6.62 percent in Last Year: Is Justifiable?May 27, 2024 | bovnews.comOpGen, Inc.: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 25, 2024 | finanznachrichten.deOpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 24, 2024 | globenewswire.comOpGen to Execute 1-for-10 Reverse Stock SplitMay 16, 2024 | 360dx.comOpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | finanznachrichten.deOpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | globenewswire.comOpGen, Inc. (OPGN) stock price, news, quote & history – Yahoo FinanceMay 4, 2024 | uk.finance.yahoo.comOpGen, Inc.: OpGen Provides Update on Business Operations and Strategic OpportunitiesApril 30, 2024 | finanznachrichten.deOpGen Provides Update on Business Operations and Strategic OpportunitiesApril 29, 2024 | globenewswire.comOpGen CEO David Lazar buys additional shares worth $150kApril 27, 2024 | investing.comOpGen, Inc.: OpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 26, 2024 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesJoby Just Flew Two Aircraft at Once—Here’s Why It MattersBy Jeffrey Neal Johnson | May 14, 2025View Joby Just Flew Two Aircraft at Once—Here’s Why It MattersGlobalFoundries Stock Hits Bottom: Is a Rebound Coming?By Thomas Hughes | May 10, 2025View GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?Why SoundHound’s Growth and Zero Debt Are a Bullish SignalBy Thomas Hughes | May 13, 2025View Why SoundHound’s Growth and Zero Debt Are a Bullish SignalIntel: Good Quarter, Bad Vibes, Guidance Rattles InvestorsBy Jeffrey Neal Johnson | April 29, 2025View Intel: Good Quarter, Bad Vibes, Guidance Rattles InvestorsCarvana’s Stock Price Rebound Shifts Into a Higher GearBy Thomas Hughes | May 8, 2025View Carvana’s Stock Price Rebound Shifts Into a Higher GearBRTX, KDLY, CCEL, and OPGN Company DescriptionsBioRestorative Therapies NASDAQ:BRTX$1.61 -0.06 (-3.59%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.66 +0.04 (+2.80%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Cryo-Cell International NYSEAMERICAN:CCEL$5.01 0.00 (0.00%) Closing price 05/16/2025 04:10 PM EasternExtended Trading$5.05 +0.04 (+0.80%) As of 05/16/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.Kindly MD NASDAQ:KDLY$12.95 -0.91 (-6.57%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$12.70 -0.25 (-1.93%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT.OpGen NASDAQ:OPGN$4.90 +0.20 (+4.26%) As of 05/16/2025 03:59 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
